1. Executive Summary (Confidence: High)

Cellvie, a spin-out from Harvard Medical School headquartered in Zürich, Switzerland, occupies a unique niche in the longevity and regenerative medicine sectors by focusing on "mitochondrial medicine". The organization is transitioning from a research-intensive startup to a clinical-stage biotechnology entity, driven by its proprietary Therapeutic Mitochondria Transplantation (TMT) platform. This technology, originally developed by Dr. James McCully, involves the transfer of healthy, viable mitochondria into cells where energy production has failed due to acute injury or aging. As of late 2025, Cellvie has secured approximately $16 million in cumulative funding, including a pivotal $5 million round in September 2025 led by Taiho Ventures to facilitate GMP-compliant manufacturing and the initiation of Phase I trials in kidney transplantation. The company’s strategic relocation to the Swiss biotech hub reflects its commitment to integrating with European healthcare networks while maintaining its foundational links to Boston’s elite medical ecosystem.